Trial Profile
Phase I Study of Soluble LAG-3 (IMP321) and Gemcitabine in Patients With Advanced Pancreas Cancer.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Eftilagimod alpha (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Adverse reactions
- 11 Mar 2009 New trial record